(Q45292749)

11 December 2017

title

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment (English)

1 reference

mild cognitive impairment

11 December 2017

main subject

1 reference

1 reference

11 December 2017

Leon J Thal

1 reference

11 December 2017

Louis Kirby

1 reference

11 December 2017

Gilbert A Block

1 reference

11 December 2017

Christopher R Lines

1 reference

11 December 2017

Eric Yuen

1 reference

11 December 2017

Christopher Assaid

1 reference

11 December 2017

Michael L Nessly

1 reference

11 December 2017

Barbara A Norman

1 reference

11 December 2017

Christine C Baranak

1 reference

11 December 2017

Scott A Reines

1 reference

11 December 2017

Rofecoxib Protocol 078 study group

1 reference

11 December 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

11 December 2017

published in

Neuropsychopharmacology

1 reference

11 December 2017

1 reference

11 December 2017

1 reference

11 December 2017

page(s)

1204-1215

1 reference

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

In-vivo measurement of activated microglia in dementia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Neuroinflammation, COX-2, and ALS--a dual role?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

1 reference

7 January 2021

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Telephone screening for amnestic mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

The Clinical Dementia Rating (CDR): current version and scoring rules

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Current concepts in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Cyclooxygenase (COX)-2 and COX-1 Potentiate β-Amyloid Peptide Generation through Mechanisms That Involve γ-Secretase Activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Clinical trial of indomethacin in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Pathological verification of ischemic score in differentiation of dementias.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

The relationship between blood pressure and dementia: a review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

COX-2 and neurodegeneration in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300690

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300690

1 reference

Dimensions Publication ID

11 December 2017

1023666178

0 references

1 reference